Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Hutchmed
Pharma
Ivonescimab, Fosun-Sitala, Hutchmed—Fierce Pharma Asia
Akeso and Summit's ivonescimab bagged its first overall survival win. Fosun inked another licensing deal. Hutchmed's CEO took medical leave. And more.
Angus Liu
Aug 29, 2025 8:15am
AZ offers early look at Datroway-Tagrisso combo in lung cancer
Mar 19, 2025 7:05pm
Roche-Innovent, AstraZeneca, Viatris and more—Fierce Pharma Asia
Jan 3, 2025 8:37am
Hutchmed inks $608M asset sale to focus on ADC development
Jan 2, 2025 11:10am
Eli Lilly partner Hutchmed scraps stomach cancer filing
Aug 30, 2024 10:39am
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
Apr 5, 2024 8:25am
